Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 6,000 Shares of Company Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $215.84, for a total value of $1,295,040.00. Following the transaction, the director owned 339,875 shares of the company’s stock, valued at approximately $73,358,620. The trade was a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $4.92 during trading on Wednesday, reaching $234.66. The company’s stock had a trading volume of 899,031 shares, compared to its average volume of 934,704. The firm has a fifty day moving average of $230.67 and a 200 day moving average of $216.80. Jazz Pharmaceuticals PLC has a one year low of $128.80 and a one year high of $266.38. The stock has a market capitalization of $15.23 billion, a PE ratio of 79.82, a P/E/G ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.04) by $0.16. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the company posted $8.13 EPS. Analysts expect that Jazz Pharmaceuticals PLC will post 10.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Penn Capital Management Company LLC purchased a new position in Jazz Pharmaceuticals during the 3rd quarter valued at about $1,009,000. AEGON ASSET MANAGEMENT UK Plc bought a new position in Jazz Pharmaceuticals during the 3rd quarter valued at approximately $2,007,000. AlphaCore Capital LLC raised its position in Jazz Pharmaceuticals by 55.4% during the 3rd quarter. AlphaCore Capital LLC now owns 1,987 shares of the specialty pharmaceutical company’s stock valued at $460,000 after purchasing an additional 708 shares during the last quarter. Retirement Systems of Alabama raised its position in Jazz Pharmaceuticals by 7.6% during the 3rd quarter. Retirement Systems of Alabama now owns 171,801 shares of the specialty pharmaceutical company’s stock valued at $39,775,000 after purchasing an additional 12,138 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Jazz Pharmaceuticals by 1,326.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 46,056 shares of the specialty pharmaceutical company’s stock worth $10,732,000 after buying an additional 42,827 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue was about $1.24 billion, up 10.4% year over year and ahead of expectations; the adjusted loss per share was also narrower than consensus. The company raised its 2026 revenue forecast to approximately $4.78 billion–$4.85 billion, above analyst estimates. JAZZ Q3 Earnings & Sales Beat Estimates, Raises ’26 Sales View
• Positive Sentiment: Jazz announced a $500 million share-buyback program, which could return capital to shareholders and support demand for the stock. Jazz Pharmaceuticals announces an equity buyback
• Positive Sentiment: JPMorgan, Morgan Stanley, RBC and Barclays raised their price targets and maintained positive ratings, signaling continued analyst optimism.
• Neutral Sentiment: The company highlighted Ziihera’s launch and its potential peak sales, as well as upcoming brain-cancer clinical data. These offer possible longer-term catalysts, but their impact will depend on commercial progress and trial results. Jazz outlines 2026 revenue guidance and Ziihera sales potential
• Negative Sentiment: Despite beating estimates, Jazz reported an adjusted loss per share, compared with earnings a year earlier. Commentary also flagged slowing growth and an action-related charge as potential concerns for investors. Jazz beats estimates but slowing growth and an action charge pose concerns

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Stifel Nicolaus set a $275.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Barclays upped their target price on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday. Needham & Company LLC increased their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, August 26th. Finally, Wall Street Zen downgraded Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 3rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $293.45.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.